British drug maker, AstraZeneca Plc, said on Friday its immunotherapy cancer treatment Imfinzi has been granted a speedy review by the U.S. medicines watchdog for the treatment of a particularly aggressive type of lung cancer. READ ALSO: EU, British council partners with NAPTIP to launch
